Marco Meglio

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is acute ischemic stroke!

A large multicenter study found that APOE genotype and a polygenic Alzheimer risk score together predict up to a 10-year difference in disease onset among people carrying an extra copy of the APP gene, whether through an APP duplication or Down syndrome.

The FDA approved Tauklarify (florquinitau F 18 injection), a tau PET imaging agent, for identifying tau neurofibrillary tangle pathology in adults being evaluated for Alzheimer disease.

The FDA has cleared Quantum BioPharma's investigational new drug application for Lucid-MS, allowing the company to begin a phase 2 trial of the first-in-class demyelination-targeting compound in progressive multiple sclerosis.

CurePSP and UCSF announced enrollment of the first participant in the PSP Trial Platform, believed to be the first platform trial ever conducted specifically for progressive supranuclear palsy, designed to test multiple investigational drugs simultaneously.

Ractigen Therapeutics announced completion of enrollment and first dosing across all cohorts of its phase 2 trial of RAG-17, an investigational siRNA therapy for SOD1-mutated ALS, building on phase 1 data recently published in Nature Medicine.

Horacio Kaufmann, MD, Director of the Dysautonomia Center at NYU Langone, discusses the prospective validation of prodromal MSA criteria, how olfactory testing can sharpen specificity, and how close the field is to biomarker-driven early diagnosis.

Annexon reported that all 10 patients in the first US and European cohort of its open-label FORWARD study showed rapid, clinically meaningful improvement in strength within days of a single tanruprubart infusion for Guillain-Barré syndrome.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Spinal Muscular Atrophy!

Investigators independently tracked the 6 patients treated in a Parkinson disease gene therapy trial that was abandoned mid-study after its sponsor became insolvent, finding a reassuring safety profile and mixed signals of motor benefit through up to 3 years.

The FDA has granted 510(k) clearance to VoxNeuro's Cognitive Function Neuroimaging software, an EEG/ERP-based tool designed to give clinicians an objective, adjunctive measure of cognitive function.

Six FDA PDUFA decisions this fall could reshape care in Alzheimer disease, DMD, Sanfilippo syndrome, Alexander disease, and SMA, here's what clinicians need to know about the data behind each.

The FDA has approved oveporexton, marketed as Orzeyful, as the first therapy to directly restore orexin signaling and address the full symptom range of narcolepsy type 1.

The associate professor at the University of Michigan covered the 2026 Peripheral Nerve Society Annual Meeting, highlighting emerging themes in GBS, SMA, TTR neuropathy, RFC1, and what is still keeping the field up at night.

The FDA has granted Regenerative Medicine Advanced Therapy designation to sasineprocel, an autologous cell therapy for Parkinson disease, based on early data from the ongoing ASPIRO trial.

The FDA has accepted Saol Therapeutics' resubmitted NDA for SL1009 in pyruvate dehydrogenase complex deficiency, setting a new PDUFA target action date of December 30, 2026.

A new cross-sectional study found that professional identity partially explains the connection between burnout and missed nursing care among neuro-oncology nurses in China, with psychological capital buffering both pathways.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is chronobiology in neurology!

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with neuro-oncologist Na Tosha Gatson, MD, PhD, FAAN. [LISTEN TIME: 20 minutes]

The nonbinding vote casts doubt on the therapy's path to approval ahead of an August 22 FDA decision, capping over a year of regulatory back-and-forth over the strength of its phase 3 data.

Stephanie Fradette, PharmD, SVP, Head of Rare Neurology Development Unit at Biogen, gave commentary on the FDA designation and long-term outlook for salanersen, an investigational antisense agent for spinal muscular atrophy.

ProMIS Neurosciences reported no cases of ARIA-E in a six-month blinded interim analysis of PMN310, an oligomer-selective antibody in the phase 1b PRECISE-AD trial for Alzheimer disease, alongside early biomarker signals consistent with target engagement.

Extended follow-up and new AAIC 2026 data show that tazbentetol, a first-in-class oral synaptic regenerative therapy, produced rapid and durable improvement in cognition and EEG biomarkers in patients with mild-to-moderate Alzheimer disease.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is tau-targeting therapies for Alzheimer disease!

A 12-week, placebo-controlled phase 2 trial found that an oral THC/CBD combination significantly reduced agitation in hospice-eligible patients with Alzheimer disease and other dementias, meeting its primary and key secondary endpoints.

Joey English, MD, Chief Medical Officer of Route 92 Medical, discusses the company's reperfusion platform, the goals of the SUMMIT RISE real-world evidence study, and what vessel-matched catheter technology could mean for acute ischemic stroke care.

Andrew Lee, MD, PhD, cofounder and CEO of Spot Biosystems, discusses the company's extracellular vesicle platform, the first non-viral delivery of full-length dystrophin in patients with Duchenne muscular dystrophy.

Epilepsy expert Susan Duberstein, MD, explores how multidisciplinary neurocutaneous clinics improve diagnosis, surveillance, care coordination, and long-term outcomes for patients with complex neurocutaneous syndromes.

The submission is backed by phase 3 FoCus trial data showing ALXN1840 tripled copper mobilization and produced significant, sustained neurologic improvement compared with standard of care over 48 weeks.

Kristen Harris, MD, Medical Director of the Extended Recovery Unit at Hackensack Meridian JFK Johnson Rehabilitation Institute, discussed new findings on functional recovery and community discharge rates in acquired brain injury patients undergoing skilled nursing facility rehabilitation.